Tiziana Life Sciences (TILS)


Latest News

Interim Results for Six Months Ended 30 June 2017

RNS Number: 1613S Tiziana Life Sciences PLC 29 September 2017 Tiziana Life Sciences plc ("Tiziana" or "the Company") Interim Results for the Six Months Ended 30 June 2017 Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need London, 29 September 2017 - Tiziana Life Sciences plc ("Tiziana", A...

Tiziana says development of oral formulation of foralumab to be used in clinical studies

Tiziana Life Sciences announced the development of a novel, proprietary, oral formulation of foralumab, a fully human ...

A Proprietary Oral Formulation of Foralumab

RNS Number: 8848P Tiziana Life Sciences PLC 06 September 2017 Tiziana Life Sciences plc ("Tiziana" or the "Company") Development of a Proprietary Oral Formulation of Foralumab, a Fully Human Anti-CD3 mAb, for use in an Upcoming Phase 2a Clinical Trial in NASH Successfully developed a novel formulation enabling oral immunotherapy with foraluma...

Grant of options - Director's dealing

RNS Number: 4431P Tiziana Life Sciences PLC 31 August 2017 Tiziana Life Sciences PLC ("Tiziana" or the "Company") Grant of options - Director's dealing London, 31 August 2017 - Tiziana Life Sciences plc (AIM: TILS, the "Company"), the clinical stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, announces that ...

All News

29-09-17Interim Results for Six Months Ended 30 June 2017RNS
06-09-17Tiziana says development of oral formulation of foralumab to be used in clinical studiesStockMarketWire
06-09-17A Proprietary Oral Formulation of ForalumabRNS
31-08-17Grant of options - Director's dealingRNS
16-08-17Tiziana converts loan notes to sharesStockMarketWire
16-08-17Conversion of outstanding loan notesRNS
28-07-17Publication of Research Article on ForalumabRNS
19-07-17Tiziana enrols first patient in Phase IIa clinical trialStockMarketWire
19-07-17Initiation of a Phase IIa Clinical TrialRNS
12-07-17Proposed changes to CLNs and Warrant TermsRNS
29-06-17Result of AGMRNS
12-06-17Appointment of Dr Kunwar Shailubhai as CEORNS
08-06-17Bcl-3 pre-clinical update and Director's dealingRNS
01-06-172016 Annual Report and Accounts and notice of AGMRNS
23-05-17Financial Results for Year Ended 31 December 2016RNS
24-04-17Broker Forecast - Beaufort Securities issues a broker note on Tiziana Life Sciences Plc Ord 3pStockMarketWire
24-04-17TILS confirms Phase II clinical trial protocol for Milciclib StockMarketWire
24-04-17Announces Approval of a Phase II Clinical TrialRNS
21-04-17Announces Publication of Milciclib Clinical TrialRNS
24-03-17Tiziana Life Sciences notes exercise of warrantsStockMarketWire
24-03-17Exercise of Warrants & Issue of EquityRNS
14-03-17Arun Sanyal appointed to Scientific Advisory BoardRNS
16-01-17Warrant Expiry - ReminderRNS
03-01-17Tiziana Life Sciences in-licences NI-1201StockMarketWire
03-01-17Tiziana Life Sciences in-licenses NI-1201RNS
16-11-16Tiziana announces new data with ForalumabStockMarketWire
16-11-16New Data with ForalumabRNS
07-11-16Tiziana CFO awarded options StockMarketWire
07-11-16Grant of optionsRNS
29-09-16Half-year ReportRNS
15-09-16Confirmation of Capital ReductionRNS
18-08-16Change of Registered OfficeRNS
18-07-16Tiziana acquires a unique bio-repositoryStockMarketWire
18-07-16Tiziana acquires a unique bio-repositoryRNS
30-06-16Result of AGMRNS
29-06-16Issue of EquityRNS
10-06-16Grant of options and realisation bonusRNS
07-06-16Tiziana Life Sciences widens FY pretax lossStockMarketWire
07-06-16Final ResultsRNS

RSS feeds

  • Editorial news feed for LSE:TILS Editorial
  • Regulatory news feed for LSE:TILS Regulatory